Health Care & Life Sciences » Biotechnology | Biotec Pharmacon ASA

Biotec Pharmacon ASA | Cash Flow

Fiscal year is January-December. All values NOK Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
22,889.00
21,993.00
17,292.00
20,389.00
24,803.00
13,828
Depreciation, Depletion & Amortization
2,306.00
2,464.00
2,927.00
1,912.00
1,978.00
2,284
Other Funds
329.00
589.00
734.00
1,773.00
1,529.00
862
Funds from Operations
20,254.00
18,940.00
13,631.00
16,704.00
21,296.00
10,682
Changes in Working Capital
2,869.00
2,260.00
745.00
2,574.00
760.00
7,597
Net Operating Cash Flow
17,385.00
21,200.00
12,886.00
19,278.00
22,056.00
18,279
Capital Expenditures
1,627.00
1,925.00
1,570.00
1,354.00
5,051.00
Sale of Fixed Assets & Businesses
-
45.00
-
-
-
Net Investing Cash Flow
1,561.00
1,877.00
1,493.00
1,347.00
5,023.00
Net Financing Cash Flow
43,223.00
77,704.00
4,440.00
46.00
-
Net Change in Cash
24,277.00
54,627.00
9,939.00
20,671.00
27,079.00
Free Cash Flow
18,697.00
22,738.00
13,656.00
19,578.00
24,685.00
Other Sources
66.00
3.00
77.00
7.00
28.00
Change in Capital Stock
43,223.00
77,704.00
4,440.00
46.00
-

About Biotec Pharmacon ASA

View Profile
Address
Siva Innovasjonssenter
Tromsø TR 9019
Norway
Employees -
Website http://www.biotec.no
Updated 07/08/2019
Biotec Pharmacon ASA is a holding company, which engages in the development, manufacture, and marketing of immunomodulatory products and cold adapted marine enzymes. It operates through the Enzymes and Beta-Glucans segments. The Enzymes segment consists of sales revenues and operating expenses associated with the subsidiary ArcticZymes AS, which develops and markets recombinant enzymes for use in life science research, molecular diagnostics, and bio-manufacturing.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.